Industry News

FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable HCC

On October 21, 2022, the U.S Food and Drug Administration (FDA) approved tremelimumab in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (HCC). 

For more information, read the FDA announcement and the AstraZeneca announcement

Posted 10/24/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us